Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells
Aree / Gruppi di ricerca
Partecipanti al progetto
- Arpicco Silvia (Coordinatore/trice)
- Milla Paola (Docente)
- Zonari Daniele (Tecnico/a)
Descrizione del progetto
Members of other units:
Marta Palmieri, Chiara Costanzo (Department of Life and Reproduction Sciences, Biochemistry Section, University of Verona)
Elisa Zoratti (Applied Research on Cancer–Network, University of Verona, Verona, Italy)
Aldo Scarpa (Department of Pathology and Diagnostics, University of Verona, Verona, Italy)
Sponsors:
Local funds University of Turin, Italy
Project Verona Nanomedicine Initiative, Italy
Description
Pancreatic adenocarcinoma is often diagnosed when metastatic events have occurred. The early spread of circulating cancer cells expressing the CD44 receptor may play a crucial role in this process. This project is based on the cellular delivery ability and both in vitro and in vivo anti-tumoral activity of liposomes conjugated with two different low molecular weight hyaluronic acids (HA 4.8 kDa and HA 12 kDa), the primary ligand of CD44, and containing a lipophilic gemcitabine pro-drug. The liposomes are fully characterized from a technological point of view and through in vitro tests.
References:
- Arpicco S. et al, 2013. European Journal of Pharmaceutics and Biopharmaceutics in press
- Dalla Pozza E. et al, 2013. BBA Biomembranes 1828, 1396–1404
Keywords:
CD44, Hyaluronic acid-conjugated liposomes, Pancreatic cancer, Active targeting